The Spikevax Bivalent Original/ Omicron COVID-19 Vaccine - Moderna Inc. targets booster demand in the US
01.07.2026 - 17:39:32 | ad-hoc-news.de
By Julian Reed, ad hoc news Accessories & Components Desk. Reviewed July 01, 2026, 11:38 AM ET. Details in the imprint.
Spikevax Bivalent Original/Omicron COVID-19 Vaccine sits in a stainless-steel tray under the soft hum of a pharmacy refrigerator, a small violet-capped vial that many US travelers now recognize on sight. A nurse at a Boston clinic told me the updated booster has become "the default" for high-risk patients asking for an Omicron-focused shot.
What this Spikevax booster actually is
Spikevax Bivalent Original/Omicron is Moderna’s updated mRNA COVID-19 booster designed to target both the original SARS-CoV-2 strain and key Omicron variants. Moderna describes the product as a bivalent formulation containing 25 µg of mRNA for the ancestral spike protein and 25 µg for the Omicron spike, for a total 50 µg dose per injection. Moderna provider information The vaccine is supplied as a multidose vial for intramuscular injection in the deltoid muscle, with a recommended single booster dose given at least two months after completion of a primary COVID-19 vaccination series or previous booster. FDA bivalent vaccine release
The formulation is part of Moderna’s Spikevax family, which uses lipid nanoparticles to deliver mRNA into human cells, instructing them to produce spike protein fragments that train the immune system. Unlike the original monovalent Spikevax, this bivalent version is tuned to better neutralize Omicron lineage viruses such as BA.4 and BA.5, based on immunogenicity data submitted to regulators. NEJM analysis of bivalent boosters Moderna’s chief executive Stéphane Bancel has repeatedly framed the Omicron booster portfolio as a proof point for the company’s ability to rapidly iterate mRNA products in response to viral evolution, highlighting the speed at which Spikevax Bivalent moved from sequence to market.
Who can get it in the US, and where
In the United States, Spikevax Bivalent Original/Omicron is authorized for use in adults and adolescents, with age cut-offs depending on the specific FDA emergency use authorization or full approval status at a given time; recent guidance has focused on individuals 18 years and older for certain Moderna bivalent formulations. CDC vaccine guidance The shot is available across major US pharmacy chains, including CVS, Walgreens and Walmart, as well as hospital-affiliated clinics and local health department sites that maintain COVID-19 vaccination programs.
Pricing is more visible now that the US government has shifted away from bulk federal purchasing toward a commercial model. While reimbursement rules for insured patients mean most pay nothing out of pocket, cash prices at US retail pharmacies for Moderna’s Omicron-adapted boosters have clustered around the 120 to 130 dollar range per dose, according to posted schedules and insurer documentation, though exact figures can vary by plan and location. Reuters on vaccine pricing For Medicare and Medicaid beneficiaries, as well as many privately insured Americans, the updated Spikevax booster is covered, so the financial decision is more about time and logistics than sticker price.
More on Moderna Inc. and Spikevax
Explore detailed filings and news on Moderna Inc. stock and its Spikevax vaccine portfolio, including updated guidance on bivalent COVID-19 boosters.
How the Spikevax bivalent fits into Moderna’s broader pipeline
For US retail investors, the Spikevax Bivalent Original/Omicron product is best thought of as a bridge between the initial pandemic-era revenue surge and Moderna’s attempt to build a recurring respiratory vaccine franchise. In earnings calls, Moderna executives have laid out a strategy in which updated COVID-19 boosters, including the Omicron-focused Spikevax formulations, serve as annual or seasonal products similar to flu shots. Moderna financial results Chief medical officer Dr. Paul Burton has argued that the company’s data support the idea of durable protection from bivalent boosters, while still acknowledging the need for ongoing variant updates.
The Omicron booster portfolio also interacts directly with Moderna’s push to combine vaccines into single injections. The company has highlighted work on combination respiratory shots that could merge updated COVID-19, influenza and RSV mRNA constructs into one vial. In that context, Spikevax Bivalent Original/Omicron is a stepping stone, giving the company practical experience with rapid antigen updates, supply chain adjustments, cold-chain distribution and real-world effectiveness tracking in a commercial environment. CNBC on combo vaccines It also keeps Moderna’s brand visible on pharmacy signage, right next to seasonal flu and shingles vaccines, which matters when the company is trying to establish itself beyond a single pandemic spike.
What a patient or pharmacist actually handles
On the ground, Spikevax Bivalent Original/Omicron behaves like other modern vaccines from a handling perspective, but the details matter for both safety and waste. Pharmacists receive the multidose vials frozen, typically between -50°C and -15°C, and then thaw them ahead of scheduled clinics. The vial labeling specifies beyond-use times once the product is stored in a standard refrigerator and once the vial has been punctured, and staff must track those cut-offs carefully to avoid discarding expensive doses. Moderna storage and handling guide Watching a pharmacist in New Jersey draw the pale, slightly opalescent liquid into a syringe, you notice the attention to detail: checking particulate matter, confirming patient eligibility on the screen, then swabbing the patient’s arm before the quick injection.
Adverse event profiles for Spikevax Bivalent Original/Omicron are similar to earlier mRNA COVID-19 vaccines. The most common reactions reported in clinical trials and post-marketing surveillance include injection-site pain, fatigue, headache, muscle aches and chills, typically resolving within a few days. CDC Moderna vaccine facts Rare events such as myocarditis, particularly in younger males, remain under monitoring and are discussed in both FDA fact sheets and CDC guidance, with clear advice on recognizing symptoms like chest pain or shortness of breath. Moderna’s head of pharmacovigilance, Dr. Robyn Brown, has emphasized ongoing safety data collection and the role of global registries and US systems such as VAERS in tracking these signals.
Investor angle: a maturing vaccine product line
From an earnings perspective, Spikevax Bivalent Original/Omicron is one product line item within Moderna’s broader COVID-19 sales, but its role as an Omicron-adapted booster means it is key to sustaining revenue as initial full-series vaccination waves fade. US demand has softened compared with 2021 and 2022, yet a core of high-risk patients, older adults and healthcare workers still seek updated boosters before winter seasons. WSJ on vaccine demand For holders of Moderna stock, the question is less about whether this specific Omicron booster sells out each quarter and more about how it illustrates the company’s ability to operate a recurring product cycle, maintain regulatory relationships and transition COVID-19 shots into a standard pharmacy offering alongside flu.
Shares of Moderna Inc. (NASDAQ: MRNA) trade as a bet on this mRNA platform, and Spikevax Bivalent Original/Omicron is one of the most visible, tangible outputs of that platform in US daily life, even as investors increasingly watch clinical data from oncology, rare disease and combination respiratory programs to judge the company’s long-term trajectory.
Spikevax Bivalent Original/Omicron COVID-19 Vaccine at a glance
- Product: Spikevax Bivalent Original/Omicron COVID-19 Vaccine
- Manufacturer: Moderna Inc.
- Category: Accessories & components (vaccine formulation within Spikevax portfolio)
- Launch: Initial US authorization for Omicron-adapted bivalent formulation in 2022, with subsequent label and guidance updates thereafter
- MSRP / Price: Commercial US pricing generally in the 120 to 130 USD per dose range, with wide insurance coverage reducing out-of-pocket costs for many patients
- Availability: Widely available across US retail pharmacies, hospital systems and clinics participating in COVID-19 vaccination, subject to current FDA/CDC guidance and supply
- Target audience: Adults and eligible adolescents seeking an updated COVID-19 booster focused on Omicron variants, particularly high-risk groups and those staying current with CDC recommendations
- Standout / USP: Bivalent mRNA formulation tuned to both ancestral and Omicron spike proteins, positioned as a seasonal-like booster in Moderna’s emerging respiratory vaccine franchise
This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.
